3-methyl-8-[1-benzylpyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione | 1019658-75-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 3-methyl-8-[1-benzylpyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione
• 英文别名: 8-(1-benzyl-1H-pyrazol-4-yl)-3-methyl-1H-purine-2,6(3H,7H)-dione；8-(1-benzylpyrazol-4-yl)-3-methyl-7H-purine-2,6-dione
• CAS: 1019658-75-3
• 化学式: C₁₆H₁₄N₆O₂
• 分子量: 322.326
• InChiKey: ZZJVLBUDTBEOFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  95.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5,6-二氨基-1-甲基尿嘧啶 、 1-苄基-1H-吡唑-4-羧酸 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 硫酸氢铵 、 六甲基二硅氮烷 作用下， 以 甲醇 为溶剂， 反应 32.0h， 生成 3-methyl-8-[1-benzylpyrazol-4-yl]-1,3,7-trihydropurine-2,6-dione
  参考文献：
  名称：

  Selective, high affinity A2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

  摘要：

  A series of N-1 monosubstituted 8-pyrazolyl xanthines have been synthesized and evaluated for their affinity for the adenosine receptors (AdoRs). We have discovered two compounds 18 (CVT-7124) and 28 (CVT-6694) that display good affinity for the A(2B) AdoR (K-i = 6 nM and 7 nM, respectively) and greater selectivity for the human A(1), A(2A), and A(3) AdoRs (> 1000-, > 830-, and > 1500-fold; > 850-, > 700-, and > 1280- fold, respectively). CVT-6694 has been shown to block the release of interleukin-6 and monocyte chemotactic protein-1 from bronchial smooth muscle cells (BSMC), a process believed to be promoted by activation of A2B AdoR. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.008

文献信息

• A2B adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050101778A1

  公开（公告）日：2005-05-12

  Disclosed are novel A 2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

  揭示了具有Formula I或Formula II结构的新型A2B腺苷受体拮抗剂：这些化合物特别适用于治疗哮喘、炎症性胃肠道疾病、心血管疾病、神经系统疾病以及与不良血管生成相关的疾病。
• A2B Adenosine receptor antagonists
  申请人：Kalla Rao

  公开号：US20050261316A1

  公开（公告）日：2005-11-24

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  揭示了一种新颖的化合物，它们是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。
• A2B ADENOSINE RECEPTOR ANTAGONISTS
  申请人：Kalla Rao

  公开号：US20080318983A1

  公开（公告）日：2008-12-25

  Disclosed are methods for treating asthma, inflammatory gastrointestinal tract disorders, cancer, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis using A 2B adenosine receptor antagonists having the structure of Formula I or Formula II:

  本发明涉及使用具有结构公式I或公式II的A2B腺苷受体拮抗剂治疗哮喘、炎症性肠道疾病、癌症、心血管疾病、神经系统疾病和与不良血管生成有关的疾病的方法。
• A2B Adenosine Receptor Antagonists
  申请人：Kalla Rao

  公开号：US20100222300A1

  公开（公告）日：2010-09-02

  Disclosed are novel compounds that are A 2B adenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

  本发明揭示了一类新的化合物，它们是A2B腺苷受体拮抗剂，可用于治疗包括哮喘和腹泻在内的各种疾病状态。
• A 2B? ADENOSINE RECEPTOR ANTAGONISTS
  申请人：CV THERAPEUTICS, INC.

  公开号：EP1444233A2

  公开（公告）日：2004-08-11